Digestive Disease Interventions 2020; 04(04): 382-388
DOI: 10.1055/s-0040-1721454
Review Article

Combination Therapies with Y90: Immunoradiation

1  Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
,
2  Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
,
Joseph P. Erinjeri
1  Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
,
Yolanda C.D. Bryce
1  Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
› Author Affiliations
Funding This research was partly funded through the NIH/NCI Cancer Center Support Grant P30 CA008748. A.R.D. reports personal fees from BTG, Inc, personal fees from Dova Pharmaceuticals, outside the submitted work. J.P.E. reports personal fees from AstraZeneca and Canon, United States, Inc.

Abstract

While much progress has been made in oncologic care, metastatic solid organ cancer still carries a poor prognosis. Immunotherapy has emerged as a promising approach, though in most patients, does not control disease when given as a monotherapy. Combining immunotherapy with locoregional therapy is one approach to boost the efficacy of treatments and potentially prolong survival. Most of the researches regarding combination therapies have involved external radiation. This review describes the immunologic effects of external radiation and radioembolization, and how these effects provide a rationale for combining hepatic radioembolization with immunotherapy.



Publication History

Received: 09 July 2020

Accepted: 06 October 2020

Publication Date:
19 November 2020 (online)

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA